Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its...
New analysis of pooled Phase 3 data will evaluate efficacy and safety of VTAMA cream across age groups in pediatric and adult patients with atopic dermatitis (AD)
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Organon & Co. ...
The launch expands Organon’s biosimilars portfolio in Canada to eight products spanning five therapeutic areas
This transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women
The amended agreement deepens Organon and Samsung Bioepis’s collaboration to six biosimilars in Canada across multiple therapeutic areas, including immunology, oncology and dermatology. ...
Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE ® (tocilizumab-bavi) injection,...
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.